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Summary Non-Hodgkin’s lymphoma (NHL) is the sixth
most common cause of cancer deaths in the U.S. Most
NHLs initially respond well to chemotherapy, but relapse is
common and treatment is often limited due to the toxicity
ofchemotherapeuticagents.Pegylated-liposomaldoxorubicin
(PLD, Ben Venue Laboratories, Inc), a produces less
myelotoxicity than non-liposomal (NL) doxorubicin. To
further enhance efficacy and NHL targeting and to decrease
toxicity, we conjugated an anti-CD22 monoclonal antibody
(HB22.7) to the surface of PLD, thereby creating CD22-
targeted immunoliposomal PLD (IL-PLD). HB22.7 was
successfully conjugated to PLD and the resulting IL-PLD
exhibitsspecificbindingtoCD22-expressingcells asassessed
by immunofluorescence staining. IL-PLD exhibits more
cytotoxicity than PLD in CD22 positive cell lines but does
not increase killing of CD22 negative cells. The IC50 of
IL-PLD is 3.1 to 5.4 times lower than that of PLD in CD22+
cell lines while the IC50 of IL-PLD is equal to that of PLD in
CD22- cells. Furthermore, IL-PLD remained bound to the
CD22+ cells after washing and continued to exert cytotoxic
effects, while PLD and NL- doxorubicin could easily be
washed from these cells.
Keywords HB22.7.CD22.Non-Hodgkin’slymphoma.
Liposomes.Doxorubicin
Abbreviations
NHL non-Hodgkin’s lymphoma
IL-PLD immunoliposomal doxorubicin (HB22.7
conjugated liposomal doxorubicin)
PLD liposomal doxorubicin
DXR doxorubicin
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NHL are a heterogeneous group of lymphoid malignancies,
80–90% of which are of B-cell origin [1]. NHL is the sixth
most common cause of cancer-related deaths in the US, with
incidence rates almost doubling since the 1970s [2]. Most
NHL are initially responsive to chemotherapy, but relapse is
common. Furthermore, the efficacy of chemotherapy is
limited by toxicity [1].
One of the most important drugs used in NHL therapy is
doxorubicin (DXR). DXR is an anthracycline antibiotic that
intercalates into DNA in rapidly dividing cells, thereby
inhibiting nucleic acid synthesis [3]. Dose-limiting toxicities
of DXR include cardiomyopathy [4] and myelosuppression
[5, 6]. Other toxicities include alopecia, hyperpigmentation
of nail beds and dermal folds, nausea, vomiting, and
stomatitis [5]. Pegylated-liposomal formulations (PLD) of
DXR (such as Doxil) have prolonged and higher expo-
sures in plasma and tumor, increased antitumor activity in
preclinical models, and reduced toxicity [7, 8]c o m p a r e d
with non-liposomal (NL) DXR. The increased DXR
accumulation in tumors and the decrease in toxicity is
thought to be due to the ability of liposomes to extravasate
through fenestrated tumor vessels, while in normal tissues,
liposomes tend to be confined in the intravascular space
since normal vessels are less fenestrated than tumor
vessels [9, 10]. However, toxicity of PLD depends on
the lipid formulation, with both fast and slow DXR release
from liposomes being least toxic, while intermediate rates
of DXR release have varying toxicities [11]. The use of
monoclonal antibodies (mAb) conjugated to liposomal
drugs (so called immunoliposomes) can further reduce
toxicity and increase efficacy by targeting the liposomal
drug to the tumor. PLD has been targeted to tumors using
anti-CD19 mAbs with success [11, 12].
CD22 is a B-lymphocyte-specific glycoprotein expressed
by nearly all mature B-lymphocytes but disappears upon
terminal maturation to plasma cells. The two amino-terminal
immunoglobulin (Ig) domains of CD22 mediate cell adhesion
with sialic-acid bearing ligands. Besides its function as a cell
adhesion molecule, CD22 also modulates signal transduction
through the B-cell receptor and upon ligation, CD22 becomes
internalized [13–15]. Anti-CD22 mAb such as HB22.7,
which bind the two amino-terminal Ig domains and
specifically block the interaction of CD22 with its ligand,
are effective at inducing proliferative responses in primary
B-cells and apoptotic responses in neoplastic B-cells [16].
By contrast, anti-CD22 mAbs that do not block ligand
binding have only modest functional effects [16, 17]. As
most NHL express CD22, it is a promising target for
immunotherapy. Targeting CD22 not only allows for
specificity, but also may facilitate intracellular drug delivery
based on CD22-mediated internalization.
We previously reported the lymphomacidal properties of
HB22.7 in nude mice bearing Raji (human B-cell NHL)
xenografts [16]. In this study, HB22.7 was conjugated to
PLD and tumor cell targeting, cell accumulation of DXR,
and cytotoxicity were assessed in vitro. The inclusion of
HB22.7 into the immunoliposome was done to specifically
target IL-PLD to the NHL, allowing more localized DXR
release and less systemic toxicity.
Materials and methods
Materials
Sephadex G-50, Sepharose CL-4B, 4-(2-hydroxyethyl)-1-
piperazine ethanesulphonic acid (HEPES), reduced Triton
X-100 and 2-iminothiolane (Traut’s reagent) were purchased
from Sigma Chemical Co. (St. Louis, MO). PLD, stericly
stabilized liposomes containing entrapped doxorubicin, was
manufactured by Ben Venue Laboratories, Inc. (Bedford,
OH). Goat anti-mouse immunoglobulins fluorescein
conjugate (goat anti-mouse Ig-FITC) was purchased from
Biosource (Camarillo, CA). BCA™ protein assay kit and
Silver SNAP II Stain Kit were purchased from Pierce
(Rockford, IL). RPMI 1640 medium, penicillin-streptomycin
and fetal bovine serum (FBS) were purchased from Life
Technologies (Carlsbad, CA). The anti-CD22 mAb, HB22.7,
was purified from ascites and has been previously character-
ized [15]. All chemicals were of analytical grade purity.
Cell lines
The human Burkitt’s B-cell lymphoma lines, Raji (ATCC
CCL-86), Ramos (ATCC CRL-1596) and the T-cell
leukemia cell line, Jurkat (ATCC TIB-152) were obtained
from American Type Culture Collection (Rockville, MD).
The cells were grown in suspension in full RPMI
(supplemented with 10% fetal bovine serum (FBS),
50 units/ml penicillin G, and 50 µg/ml streptomycin
sulfate). The cells were maintained in tissue culture flasks
at 37°C in 5% CO2 and 90% humidity.
Preparation of anti-CD22 MAb (HB22.7)-targeted IL
by the post-insertional method
PLD (Doxil®), a pegylated-liposomal formulation of DXR
was prepared and characterized at ALZA Corp. as
described previously [18]. The anti-CD22 mAb, HB22.7,
was conjugated to PLD using a previously described post-
insertional method for transfer of ligands to pre-formed
liposomes [19]. Briefly, mAb-coupled micelles were pre-
pared as follows. Mal-PEG-DSPE and mPEG-DSPE were
mixed at a 4:1 molar ratio and dried under nitrogen gas until
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speed vacuum for an additional 4 h. The dried lipid films
were hydrated immediately before mAb coupling to a
concentration of 10 mmol/L in deoxygenated 25 mmol/L
HEPES (pH 7.4) by heating in a 65°C water bath. MAb
HB22.7 (10 mg/ml) was incubated with 2-iminothiolane in
HEPES-buffered saline (pH 8.0) at a molar ratio of 10:1 for
1 h at room temperature to thiolate the mAb’s amino groups.
The thiolated mAb was then chromatographed over a
Sephadex G-50 column equilibrated with HEPES-buffered
saline (pH 7.4) and immediately incubated with hydrated
micelles overnight under nitrogen gas with continuous
stirring. After mAb coupling to micelles, the micelles were
incubated with pre-formed liposomes (PLD) at a molar ratio
of 0.05:1 for 1 h at 60°C. The micelle/PLD mixture was then
chromatographed over a Sepharose CL-4B column equilibrat-
ed in pyrogen-free HEPES-buffered saline (pH7.4) to separate
the immunoliposomes (IL-PLD) from PEG-micelles and free
mAb. The amount of mAb conjugated to the liposomes was
quantified by the BCA™ protein assay kit and the coupling
ratio (µg IgG/µmol liposome phospholipid) was calculated.
Phospholipid concentration was determined by the Fiske and
Subbarow method [20]. The concentration of the liposome-
entrapped DXR was determined by spectrophotometry (l=
490 nm) and the size of resulting IL-PLD was determined by
dynamic light scattering using a Beckman Coulter N4 MD
sub-micron particle analyzer (Fullerton, CA).
In-vitro cytotoxicity assays
Raji (CD22+), Ramos (CD22+), or Jurkat (CD22-) cells
(5×10
4) were plated in 96 well, round bottom plates in a
volume of 100 μl. NL-DXR, PLD and IL-PLD were
serially diluted 1:2 with medium to achieve final concen-
trations of 001–5.0ug/ml. All samples were plated in
triplicate. The plates were incubated at 37°C, 5% CO2
and 90% humidity for 1 h, centrifuged, and the cells
washed with PBS three times. Following the final wash,
cells were re-suspended in 200 μl of full RPMI1640
medium and returned to the incubator for 71 h. In some
cytotoxicity assays, the cells were treated with the drugs
continuously (no washing) for 72 h. A trypan blue
exclusion assay was used to measure viability. The dose
response logistic equation was applied to the data, and the
IC50 was read from the curve.
Immunofluorescence imaging
Raji (CD22+), Ramos (CD22+), or Jurkat (CD22-) cells
(1×10
6) were incubated with IL-PLD/ml (5 μg) for 1 h on
ice. The cells were washed three times with cold PBS,
pH 7.4, to remove unbound IL-PLD and incubated with
FITC-labeled goat anti-mouse Ig for 1 h on ice. Cells were
again washed three times with PBS, then fixed with 2%
paraformaldehyde. Images were then acquired (Olympus
Motorized Reflected Fluorescence System BX61).
IL-PLD accumulation in CD22 expressing NHL cells
Raji cells (CD22 +) were plated in six well plates at 2×10
6
cells/well. Cells were treated with IL-PLD or PLD at final
concentrations of 0, 0.5 μg/ml, 1 μg/ml, 2 μg/ml, 4 μg/ml
and 8 μg/ml for 2 h at 37°C. The cells were washed three
times with cold PBS. DXR was then extracted by acidified
isopropanol (75 mM hydrochloric acid in 90% isopropanol)
for 20 h at 4°C. DXR concentration extracted from the cells
was assayed by microflourometer, using 470 nm as the
excitation and 590 nm as the emission wavelength.
SDS-PAGE
HB22.7, PLD, and IL-PLD were run on a 10% polyacryl-
amide gel, followed by silver staining with the Pierce
SilverSNAP Stain Kit II according to manufacturer’s
instructions.
DXR in vitro release assay (DXR leakage assay)
PLD and IL-PLD were freshly prepared and NL-DXR, if
any, was separated from the liposomal suspensions by
elution over a Sepharose CL-4B column. PLD and IL-PLD
were then dialyzed for 24 h, 48 h, 72 h, or 96 h against PBS
pH 7.4 at 37°C. The percentage release of DXR was analyzed
by fluorescence de-quenching measured using 485 nm as the
excitation wavelength and 590 nm as the emission wave-
length. Complete release (100% de-quenching) of DXR was
obtained by lysing PLD or IL-PLD in 50 μl of 10% (v/v)
reduced Triton X-100 inPBS per mL of liposome suspension.
Results
Characterization of IL-PLD
The anti-CD22 mAb, HB22.7, was conjugated to PLD as
described above. IL-PLD was analyzed via SDS-PAGE to
confirm that HB22.7 was incorporated into PLD as shown in
Fig. 1a. PLD or IL-PLD were then dialyzed against PBS for
24, 48, 72, and 96 h and the amount of DXR in the dialysate
quantified to determine DXR leakage from the liposomes
(Fig. 1b). No difference was seen in the amount of DXR
leakage from PLD and IL-PLD. For example, IL-PLD and
PLD at 96 h of dialysis displayed 8.6% versus 7.5% DXR
leakage, respectively (Fig. 1b). The mean ± SD diameters of
PLD and IL-PLD were determined to be 118±__nm and
165±__nm respectively (Fig. 1c). The mean diameters of
262 Invest New Drugs (2010) 28:260–267PLD and IL-PLD were reduced by 25% and 26%,
respectively, when size was measured in PBS containing
50% FBS (Fig. 1c).
IL-PLD targets CD22 expressing NHL cell lines
After determining that HB22.7 was incorporated into PLD,
thereby creating IL-PLD (Fig. 1a), it was important to
determine that IL-PLD was indeed able to bind CD22
expressing cells. Binding was assessed by fluorescence
microscopy using a goat anti-mouse IgG-FITC against the
HB22.7 mAb component of IL-PLD. IL-PLD binds to two
different B-cell (CD22+) Burkitt’s lymphoma cell lines,
Raji and Ramos, but did not bind to the Jurkat T-cell
leukemia (CD22-) cell line, (Fig. 2).
NHL cell line treated with IL-PLD exhibit increased DXR
accumulation compared to PLD treatment
After determining that IL-PLD can bind to CD22+NHL
cells, we sought to determine if the inclusion of the HB22.7
targeting mAb in IL-PLD enabled more DXR uptake in
NHL cells as compared to unmodified PLD. Raji cells
(CD22+) were treated with increasing concentrations of
either IL-PLD or PLD. After 2 h, cells were washed to
remove any remaining drug, and DXR that had accumulated
in the cells was extracted. Cells treated with PLD showed
DXR accumulation only at the highest dose (8 μg/mL), while
cells treated with IL-PLD exhibited increasing DXR accumu-
lation beginning at the 1 μg/mL dose (Fig. 3).
NHL cell lines exhibit more cytotoxicity with IL-PLD
treatment compared to PLD treatment
We next compared the cytotoxic effects of IL-PLD to PLD
and NL-DXR. Raji (CD22+) or Jurkat (CD22-) cells were
incubated for 72 h with increasing doses of IL-PLD, PLD, or
NL-DXR and cytotoxicity assessed by trypan blue exclusion
assay (Fig. 4). IL-PLD exhibited more cytotoxicity than PLD
in the CD22+ cell line (Fig. 4a, c). There was no difference
between IL-PLD and PLD treatments in the CD22- cell line
(Fig. 4b, d). At lower concentrations, both IL-PLD and PLD
were less cytotoxic than NL-DXR in both CD22+ and CD22-
cells (Fig. 4a, b). For CD22+ cells, the IC50 of IL-PLD was
lower than that of PLD (0.07 μg/mL versus 0.22 μg/mL for
Raji and 0.16 μg/mL versus 0.89 μg/mL for Ramos (Fig. 4c
and Table 1). For CD22- Jurkat cells, the IC50 of IL-PLD was
similar to that of PLD (0.11 μg/mL versus 0.10 μg/mL)
(Fig. 4da n dT a b l e1). Since continuous in vitro treatment for
72 h does not accurately reflect conditions that would occur
in the blood circulation in vivo, we compared continuous
72 h in vitro treatment with 1 h treatment followed by
several washes, replacement with fresh treatment-free media,
and assessment 71 h later (Fig. 5 and Table 2). The
cytotoxicity of IL-PLD, PLD, and NL-DXR decreases under
washing conditions (Fig. 5b) versus continuous treatment
(Fig. 5a). There is a 3-fold increase in the IC50 of IL-PLD
under washing conditions compared to continuous treatment,
while there is an 11- and 43-fold increase in the IC50 of PLD
and NL-DXR, respectively, under washing conditions
compared to continuous treatment (Table 2).
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Fig. 1 Post-insertional method for preparation of immunoliposomes.
a SDSzPAGE analysis of free mAb (HB22.7), PLD, and IL-PLD.
Arrows indicate expected sizes of mAb heavy and light chains. b
DXR released from IL-PLD and PLD dialyzed against PBS. c Mean
diameter (nm) of IL-PLD and PLD measured in PBS or PBS
containing 50% FCS. The 95% range values are given in parentheses
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Liposomal formulations of chemotherapy, such as PLD, can
offer increased efficacy and reduced toxicity compared to
their non-carrier mediated formulations, such as DXR [7].
With the inclusion of mAbs on the liposomal surface,
immunoliposomes can offer even greater efficacy enhance-
ment and toxicity reduction versus unmodified/non-targeted
liposomal agents. The anti-CD22 mAb, HB22.7, has been
shown to cause tumor regression in nude mice bearing Raji
xenografts [16]. To combine the cytotoxicity of PLD and
HB22.7 we We conjugated HB22.7 to PLD, creating a
CD22 targeted immunoliposomal form of PLD (IL-PLD).
SDS-PAGE confirmed that HB22.7 was indeed incorpo-
rated into PLD (Fig. 1a, right lane). The percentage of DXR
that was released from the liposome was similar for PLD
and IL-PLD (Fig. 1b). This indicates that the liposome’s
structural stability was not altered by insertion of the
HB22.7 mAb. IL-PLD’s mean diameter is only slightly
larger than PLD’s (165 nm versus 118 nm) and the mean
diameter is reduced by the same percentage when size is
measured in buffer containing 50% FBS (26% and 25%
reduction for IL-PLD and PLD, respectively) (Fig. 1c).
Liposome size is an important factor as larger liposomes
will have more difficulty crossing the blood vessel
endothelium to enter the tumor and may be cleared faster
by the reticuloendothelial system. Fenestrated tumor vessels
usually contain pore sizes from 100–780 nm and liposomes
with diameters of 100–200 nm readily extravasate into the
local tumor environment [21]. Assessing liposome size in
buffer containing 50% FBS may more accurately predict
what the actual size of the liposome will be as part of
biological solutions, preclinical animal models, and in
patients. Moreover, the IL-PLD falls well within the 100–
200 nm range, even without measurement in 50% FBS.
The rationale for incorporating the anti-CD22 mAb,
HB22.7, onto PLD’s surface was to further enhance
efficacy and decrease toxicity by targeting PLD to CD22
expressing NHLs. IL-PLD is indeed able to bind to CD22
expressing NHL cell lines (Fig. 2a, c) but does not bind to a
CD22 negative cell line (Fig. 2d). The HB22.7 component
Fig. 2 IL-PLD binds to CD22+
cells but not CD22- cells.
Burkitt’s B-lymphoma cells
(CD22+) Raji (a) and Ramos
(c) or T cell leukemia (CD22-)
Jurkat (d) were incubated with
5 μg IL-PLD/ml for 1 h on ice.
Panel b is a negative control
(Raji cells incubated with goat
anti-mouse Ig only (no IL-PLD).
Cells were washed three times
with cold PBS to remove the
unbound IL-PLD and incubated
with FITC-labeled goat
anti-mouse Ig for 1 h. Cells
were again washed three times
with PBS and fixed with
2% paraformaldehyde and
images were acquired with a
fluorescence microscope. (a),
(b) and (d) are 40× and (c)i s
60× magnification
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Fig. 3 DXR accumulation in NHL cell lines is greater with IL-PLD
treatment than with PLD. Raji (CD22+) cells were plated in six well
plates at 2×10
6 cells/well. The final concentrations of IL-PLD or PLD
were 0, 0.5 μg/mL, 1 μg/mL, 2 μg/mL, 4 μg/mL and 8 μg/mL. Cells
were treated for 2 h at 37°C, then washed and DXR extracted with
acidified isopropanol. DXR concentration was determined by micro-
flourometer. p value ≤0.001
264 Invest New Drugs (2010) 28:260–267of IL-PLD maintains the same binding specificity as the
free parent mAb.
Other groups have created immunoliposomal forms of
PLD using anti-CD19 and anti-CD20 mAbs [11, 12]. Anti-
CD19 immunoliposomal PLD exhibits greater efficacy than
PLD in vivo, while anti-CD20 immunoliposomal PLD
shows little improvement over PLD [11, 12]. CD19 is an
internalizing epitope, while CD20 is a non-internalizing
epitope and previous studies have shown that internalizing
epitopes are needed for efficient delivery of liposomal
drugs into their target cells [22]. Like CD19, our target,
CD22, is an internalizing epitope and HB22.7 causes CD22
internalization upon binding [23]. As the HB22.7 compo-
nent of IL-PLD internalizes, the liposome will be delivered
into the cell. This will allow more DXR to be released into
the targeted cell and enhance the cytotoxic effect compared
to non-targeted PLD. CD22 is a potentially a better target
than CD19 for immunoliposomal DXR therapies. A recent
study shows that immunotoxins targeted to CD22 exhibit
greater internalization and cytotoxicity than immunotoxins
Doxorubicin PLD IL-PLD P value (PLD
vs IL-PLD)
Ramos 0.0310±0.0250 0.8890±0.0276 0.1640±0.0375 ≤0.001
Raji 0.0028±0.0001 0.2246±0.0746 0.0717±0.0237 ≤0.005
Jurkat 0.0055±0.0023 0.0956±0.0272 0.1052±0.0459 0.7707
Table 1 IC50 of cell lines con-
tinuously treated with IL-PLD,
PLD, and NL- DXR for 72 h
Data is average of three experi-
ments for each cell line. P value is
for IL-PLD versus PLD groups
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Fig. 4 IL-PLD shows increased cytotoxicity compared to PLD in
CD22+ but not CD22- cell lines. CD22+Raji (a, c) or CD22- Jurkat
(b, d) were treated with increasing doses of IL-PLD, PLD, or NL-
DXR and viability assessed by trypan blue exclusion. Panels c and d
include IC50 calculations
Invest New Drugs (2010) 28:260–267 265targeted to CD19, despite similar cell binding affinities
between the two immunotoxins and the fact that there are
fewer CD22 binding sites per cell than CD19 binding sites
[24]. Figure 3 shows that DXR accumulation in CD22+
cells after 1 h of IL-PLD treatment occurs at 1ug/mL and
increases as the dose increases, while DXR accumulation
after 1 h of PLD treatment only occurs at the highest dose
tested (8 μg/mL). Increased DXR accumulation also
correlates with increased cytotoxicity. Figure 4a, 4c and
Table 1 demonstrate that IL-PLD shows more cytotoxicity
and has a lower IC50 than PLD in CD22+ NHL cells. It is
also important to note that IL-PLD’s increase in cytotoxicity
is specific for CD22+ cells, as a CD22- cell line showed no
difference in cytotoxicity or IC50 between IL-PLD and PLD
(Fig. 4b, d, and Table 1).
Though IL-PLD is more cytotoxic than PLD in CD22+
cells, both IL-PLD and PLD are less cytotoxic than
NL-DXR in both CD22+ and CD22- cells (Fig. 4a, c, and
Table 1). NL-DXR is a highly cytotoxic and non-specific
(untargeted) drug with a large volume of distribution [25],
which explains DXR’s adverse effects such as cardiomyop-
athy [4] and myelosuppression [5, 6]. If NHL cells are
treated for a short period of time, then washed, the cytotoxic
effects of NL-DXR should decrease to a greater extent than
that of PLD or IL-PLD. Due to the HB22.7’s ability to keep
IL-PLD bound to the cell, IL-PLD’s cytotoxic effects should
be the least affected by washing. To test this, we compared
treating cells with NL-DXR, PLD, or IL-PLD continuously
for 72 h, and treating cells for only 1 h followed by several
washes and re-plating of the cells in fresh, treatment-free
medium for 71 h. Figure 5 and Table 2 demonstrate that the
cytotoxicities of all three treatments in CD22+Ramos cells
decrease under washing conditions versus continuous treat-
ment.However,themagnitudeofthedecreasesincytotoxicity
vary dramatically depending on the treatment (Table 2). NL-
DXR under washing conditions exhibits a large 43.8-fold
increase in IC50 over continuous treatment (1.35 μgv e r s u s
0.03 μg/mL), PLD under washing conditions exhibits an
11.2-fold increase in IC50 over continuous treatment
(9.96 μg/mL versus 0.88 μg/mL), and IL-PLD under
washing conditions exhibits a 3.01-fold increase in IC50
over continuous treatment (0.50 μg/mL versus 0.16 μg/mL)
(Table 2, B/A ratio). This demonstrates that IL-PLD remains
bound to the NHL cells and continues to exert cytotoxic
effects, while PLD and especially NL-DXR are more easily
separated from the cells, sparing the cells from their
cytotoxic effects. This has important in vivo implications as
the blood circulation will act to “wash” chemotherapy away
from their intended targets. The inclusion of HB22.7 on IL-
PLD will better resist such clearing away by the circulation
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Fig. 5 IL-PLD shows enhanced
cytotoxicity compared to PLD
when washing conditions are
used to mimic in vivo circulation.
Ramos cells (CD22+) were
treated with increasing doses of
IL-PLD, PLD, or NL-DXR for
either 72 h continuously (a), or
for 1 h, followed by three washes
and replacement with treatment-
free media, and incubated for
71 h (b), then assessed by trypan
blue exclusion
Table 2 IL-PLD growth inhibitory effects on CD22+ cell line are
enhanced compared to PLD under washing conditions
A. IC50
Continuous
treatment
B. IC50 Wash
after 1h of
treatment
B/A
Doxorubincin 0.031 1.359 43.8
PLD 0.889 9.967 11.2
IL-PLD 0.164 0.505 3.01
The IC50 values for Fig. 6 are shown along with a ratio of the IC50
under washing conditions : IC50 under continuous treatment con-
ditions (B/A)
266 Invest New Drugs (2010) 28:260–267and thus IL-PLD should show more in vivo efficacy in NHL
tumors than PLD or NL-DXR. Furthermore, the specificity
of HB22.7 for CD22 should allow IL-PLD to be less toxic
compared with NL-DXR, as only the CD22 expressing NHL
tumor will be targeted, sparing other healthy tissues.
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